WallachBeth Capital Closes $3.2 Million bioAffinity Technologies Offering
WallachBeth Capital LLC announced June 18, 2026, that it has closed a $3.2 million offering for bioAffinity Technologies, Inc., a Nasdaq-listed biotechnology company. The Jersey City, N.J.-based capital markets firm served as placement agent on the transaction for bioAffinity, which trades on Nasdaq under the tickers BIAF and BIAFW.
WallachBeth Capital LLC announced June 18, 2026, that it has closed a $3.2 million offering for bioAffinity Technologies, Inc., a Nasdaq-listed biotechnology company. The Jersey City, N.J.-based capital markets firm served as placement agent on the transaction for bioAffinity, which trades on Nasdaq under the tickers BIAF and BIAFW.
The Transaction
WallachBeth Capital confirmed the offering closed but the announcement did not disclose the deal's structure — whether the raise consisted of common shares, warrants, or a combination of instruments — nor did it detail the intended use of proceeds. The $3.2 million figure represents the total size of the completed offering.
About bioAffinity Technologies
bioAffinity Technologies is a biotechnology company focused on the need for noninvasive solutions, according to its description in the announcement. The company is publicly traded on Nasdaq under two listings: common shares under BIAF and warrants under BIAFW. The press release summary does not specify bioAffinity's development stage, product pipeline, or commercial status beyond that characterization.
WallachBeth Capital's Role
WallachBeth Capital describes itself as a leading provider of capital markets and institutional execution services. Headquartered in Jersey City, N.J., the firm acted as the named agent on the bioAffinity close. The announcement did not identify co-agents or participating institutional investors.
Note: The source press release summary was truncated. This article reflects only the facts contained in the available text.